Laparoscopic Versus Open Resection of Hepatocellular Carcinoma in Patients with Cirrhosis: Meta-analysis
Overview
Authors
Affiliations
Background: The exact role of laparoscopic liver resection (LLR) in patients with hepatocellular carcinoma (HCC) and underlying liver cirrhosis (LC) is not well defined. In this meta-analysis, both long- and short-term outcomes following LLR versus open liver resection (OLR) were analysed.
Methods: PubMed, EMBASE, Scopus and Web of Science databases were searched systematically for randomised controlled trials (RCTs) and propensity-score matched (PSM) studies reporting outcomes of LLR versus OLR of HCC in patients with cirrhosis. Primary outcome was overall survival (OS). This was analysed using one-stage (individual participant data meta-analysis) and two-stage (aggregate data meta-analysis) approaches. Secondary outcomes were operation duration, blood loss, blood transfusion, Pringle manoeuvre utilization, overall and major complications, length of hospital stay (LOHS), 90-day mortality and R0 resection rates.
Results: Eleven studies comprising 1618 patients (690 LLR versus 928 OLR) were included for analysis. In the one-stage meta-analysis, an approximately 18.7 per cent lower hazard rate (HR) of death in the LLR group (random effects: HR 0.81, 95 per cent confidence interval [C.I.] 0.68 to 0.96; P = 0.018) was observed. Two-stage meta-analysis resulted in a pooled HR of 0.84 (95 per cent C.I. 0.74 to 0.96; P = 0.01) in the overall LLR cohort. This indicated a 16-26 per cent reduction in the HR of death for patients with HCC and cirrhosis who underwent LLR. For secondary outcomes, LLR was associated with less blood loss (mean difference [MD] -99 ml, 95 per cent C.I. -182 to -16 ml), reduced overall complications (odds ratio 0.49, 95 per cent C.I. 0.37 to 0.66) and major complications (odds ratio 0.45, 95 per cent C.I. 0.26 to 0.79), and shorter LOHS (MD -3.22 days, 95 per cent C.I. -4.38 to -2.06 days).
Conclusion: Laparoscopic resection of HCC in patients with cirrhosis is associated with improved survival and perioperative outcomes.
Zhao F, Zhang T, Yang Q, Zhang X, Yang F, Qian N Sci Rep. 2024; 14(1):28350.
PMID: 39550438 PMC: 11569221. DOI: 10.1038/s41598-024-79416-w.
Xu H, Liu Y, Wei Y Surg Endosc. 2024; 38(11):6456-6463.
PMID: 39266759 DOI: 10.1007/s00464-024-11239-2.
Zhang Z, Du Y, Wei S, Pei W Front Oncol. 2024; 13:1327147.
PMID: 38486931 PMC: 10937467. DOI: 10.3389/fonc.2023.1327147.
Robotic Complete ALPPS (rALPPS)-First German Experiences.
Arend J, Franz M, Rose A, March C, Rahimli M, Perrakis A Cancers (Basel). 2024; 16(5).
PMID: 38473426 PMC: 10930461. DOI: 10.3390/cancers16051070.
Vitale A, Angelico R, Sensi B, Lai Q, Kauffmann E, Scalera I Cancers (Basel). 2024; 16(5).
PMID: 38473327 PMC: 10930835. DOI: 10.3390/cancers16050966.